Lexicon Pharmaceuticals (LXRX) Depreciation & Amortization (CF) (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Depreciation & Amortization (CF) of $110000.0 for Q1 2026, down 37.5% year-over-year from $176000.0 in Q1 2025, and down 6.78% quarter-over-quarter from $118000.0 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $110000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $110000.0, down 37.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $555000.0 (down 1.94% YoY), and the FY2025 annual result was $621000.0, up 16.29% from the prior year.
- Depreciation & Amortization (CF) retreated to $110000.0 in Q1 2026 per LXRX's latest filing, from $118000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $176000.0 in Q1 2025 and troughed at $103000.0 in Q4 2022.
- A 5-year average of $132117.6 and a median of $126000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) jumped 194.59% in 2022, then slumped 37.5% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $103000.0 in 2022, then surged by 42.72% to $147000.0 in 2023, then fell by 14.97% to $125000.0 in 2024, then dropped by 5.6% to $118000.0 in 2025, then decreased by 6.78% to $110000.0 in 2026.
- Business Quant data shows LXRX's Depreciation & Amortization (CF) at $110000.0 in Q1 2026, $118000.0 in Q4 2025, and $151000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Lexicon Pharmaceuticals | 804.48 Mn | 633.82 Mn | 20.99 Mn | 110,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 110,000.00 |
| Mar 31, 2026 | 110,000.00 |
| Dec 31, 2025 | 118,000.00 |
| Dec 31, 2025 | 118,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Jun 30, 2025 | 176,000.00 |
| Jun 30, 2025 | 176,000.00 |
| Mar 31, 2025 | 176,000.00 |
| Mar 31, 2025 | 176,000.00 |
| Dec 31, 2024 | 125,000.00 |
| Dec 31, 2024 | 125,000.00 |
| Sep 30, 2024 | 126,000.00 |
| Sep 30, 2024 | 126,000.00 |
| Jun 30, 2024 | 139,000.00 |
| Jun 30, 2024 | 139,000.00 |
| Mar 31, 2024 | 144,000.00 |
| Mar 31, 2024 | 144,000.00 |
| Dec 31, 2023 | 147,000.00 |
| Dec 31, 2023 | 147,000.00 |